These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 22571693)

  • 1. World Health Organization classification of myelodysplastic syndromes.
    Czader M; Orazi A
    Curr Pharm Des; 2012; 18(22):3149-62. PubMed ID: 22571693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelodysplastic syndromes.
    Zhou J; Orazi A; Czader MB
    Semin Diagn Pathol; 2011 Nov; 28(4):258-72. PubMed ID: 22195404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms.
    Vardiman JW
    Chem Biol Interact; 2010 Mar; 184(1-2):16-20. PubMed ID: 19857474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classification and prognostic evaluation of myelodysplastic syndromes.
    Cazzola M; Della Porta MG; Travaglino E; Malcovati L
    Semin Oncol; 2011 Oct; 38(5):627-34. PubMed ID: 21943669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions.
    Valent P; Horny HP
    Eur J Clin Invest; 2009 Jul; 39(7):548-53. PubMed ID: 19453651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative review of classification systems in myelodysplastic syndromes (MDS).
    Bennett JM
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
    Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytogenetics and molecular genetics of myelodysplastic neoplasms.
    Ning Y; Zhang Y; Kallen MA; Emadi A; Baer MR
    Best Pract Res Clin Haematol; 2023 Dec; 36(4):101512. PubMed ID: 38092472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and classification of myelodysplastic syndromes.
    Hasserjian RP; Germing U; Malcovati L
    Blood; 2023 Dec; 142(26):2247-2257. PubMed ID: 37774372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proposed changes in the definitions of acute myeloid leukemia and myelodysplastic syndrome: are they helpful?
    Head DR
    Curr Opin Oncol; 2002 Jan; 14(1):19-23. PubMed ID: 11790975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification.
    Font P; Loscertales J; Benavente C; Bermejo A; Callejas M; Garcia-Alonso L; Garcia-Marcilla A; Gil S; Lopez-Rubio M; Martin E; Muñoz C; Ricard P; Soto C; Balsalobre P; Villegas A
    Ann Hematol; 2013 Jan; 92(1):19-24. PubMed ID: 22948274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Re-evaluation of classification of myelodysplastic syndromes with low percentage bone marrow blasts].
    Yu MH; Xu ZF; Li L; Nie L; Liu L; Zhang Y; Qin TJ; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):3-7. PubMed ID: 19563026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide analysis of myelodysplastic syndromes.
    Sanada M; Ogawa S
    Curr Pharm Des; 2012; 18(22):3163-9. PubMed ID: 22571694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelodysplastic syndromes.
    Sultan C; Imbert M; Jouault H; Scoazec JY
    Acta Haematol; 1987; 78 Suppl 1():91-3. PubMed ID: 3124454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current approach to the diagnosis of myelodysplastic syndromes
    Weinberg OK; Hasserjian RP
    Semin Hematol; 2019 Jan; 56(1):15-21. PubMed ID: 30573039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cytogenetics of myelodysplastic syndromes and its impact as prognostic factor].
    Borjas-Gutiérrez C; Domínguez-Cruz MD; González-García JR
    Rev Med Inst Mex Seguro Soc; 2017; 55(4):481-489. PubMed ID: 28591503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.